Nemluvio is a medicine used to treat adults and adolescents aged 12 years and older who have atopic dermatitis (also known as atopic eczema, when the skin is itchy, red and dry) or adults with moderate-to-severe prurigo nodularis (a long-term skin disease with a rash causing lumps with intense itching). It can be used when the patient can be treated with systemic treatments (a medicine given by mouth or injection). Nemluvio contains the active substance nemolizumab.
Therapeutic Indication
### Therapeutic indication Atopic dermatitis (AD) Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy. Prurigo nodularis (PN) Nemluvio is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
Therapeutic Area (MeSH)
ATC Code
D11AH12
ATC Item
nemolizumab
Pharmacotherapeutic Group
Other dermatological preparations
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| nemolizumab | N/A | Nemolizumab |
EMA Name
Nemluvio
Medicine Name
Nemluvio
Aliases
N/ANo risk management plan link.
